510(k)s Are Subject To Good Laboratory Practice Regs – FDA Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers must declare compliance or explain noncompliance to good laboratory practice regulations for nonclinical studies in all pre-market submission types, according to a new draft guidance. This has not been the requirement for 510(k)s up until now, says the former CDRH 510(k) policy chief.
You may also be interested in...
510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing
Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.